Clinical Trials
18 trialsNCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05949632 2025-08-03
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT04873895 2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT02782403 2020-11-19
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT01599754 2019-09-20
ATLAS
SFJ Pharmaceuticals, Inc.
Phase 3 Terminated
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01533948 2018-05-09
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01508117 2017-09-19
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
University of Cincinnati
Phase 2 Terminated
NCT01483638 2016-05-12
TTD-11-01
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Terminated